Johnson & Johnson chief executive Alex Gorsky says all three of its business segments are doing well and made significant medical advances last year.
Gorsky told shareholders at the annual meeting that J&J is poised to lead the health care industry, noting approvals and launches of several new prescription medicines and medical devices last year.
Just Wednesday, the company got its latest prescription drug approved: Sylvant, for the rare blood disorder Castleman's disease.
Meanwhile, most of its recalled consumer health products such as Tylenol now back in stores have regained top market positions.
The meeting drew several patients protesting products they said had harmed them, particularly pelvic mesh implants.
The sling-like mesh strips, used to lift sagging pelvic organs, have been linked to crippling pain, infections and other complications.
